Title

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    35
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver. The protein-acetaminophen product is called an "adduct." After a large acetaminophen overdose, the liver has to process a lot of acetaminophen, so large amounts of adducts are formed. However, we have found that lower levels may be formed even when people take recommended doses. The purpose of this study is to measure the amount of adducts formed when healthy people who do not drink alcohol take normal doses of acetaminophen for 10 days.
Study Started
Aug 31
2007
Primary Completion
Jan 31
2008
Study Completion
Jan 31
2008
Results Posted
Jul 12
2012
Estimate
Last Update
Jul 12
2012
Estimate

Drug acetaminophen

4 g/day for 10 consecutive days

  • Other names: Tylenol Extra Strength

A Experimental

all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study

Criteria

Inclusion Criteria:

age 21 years or older
provide written informed consent
consume, on average, less than 1 alcoholic beverage daily for the previous 3 months and would be considered non-drinkers

Exclusion Criteria:

History of ingesting more than 4 grams of acetaminophen per day for any of the 4 days preceding study enrollment
Currently taking isoniazid
Consumption of any alcoholic beverage during the run-in period
A detectable serum acetaminophen at baseline
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 50 IU/L at the start of the run-in period or at baseline
Platelet count less than 125,000/cc at baseline
Positive pregnancy test at baseline (female participants only)
Currently adheres to a fasting type diet as determined by self report
Currently has anorexia nervosa as determined by self report
Subject appears clinically intoxicated, psychiatrically impaired or unable to give informed consent for any reason
Known hypersensitivity to acetaminophen

Summary

Acetaminophen

All Events

Event Type Organ System Event Term Acetaminophen

Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts

Acetaminophen-cysteine (APAP-Cys) protein adduct concentrations were measured at Day 0, 4, 7, 9, 11 and 14. All units are in nmol/mL serum.

Acetaminophen

Day 0

Day 11

0.4
nmol/mL (Mean)
Standard Deviation: 0.2

Day 14

0.2
nmol/mL (Mean)
Standard Deviation: 0.1

Day 4

0.3
nmol/mL (Mean)
Standard Deviation: 0.1

Day 7

0.3
nmol/mL (Mean)
Standard Deviation: 0.2

Day 9

0.4
nmol/mL (Mean)
Standard Deviation: 0.2

Alanine Aminotransferase (ALT)

ALT was measured at Day 0, 4, 7, 9, 11, and 14.

Acetaminophen

Day 0

24.0
IU/L (Mean)
Standard Deviation: 8.1

Day 11

41.8
IU/L (Mean)
Standard Deviation: 24.2

Day 14

36.1
IU/L (Mean)
Standard Deviation: 18.6

Day 4

25.9
IU/L (Mean)
Standard Deviation: 10.1

Day 7

41.3
IU/L (Mean)
Standard Deviation: 27.3

Day 9

41.3
IU/L (Mean)
Standard Deviation: 27.3

Age Continuous

37.3
years (Mean)
Standard Deviation: 12.2

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Acetaminophen

Drop/Withdrawal Reasons

Acetaminophen